Back to top
more

Aerie Pharmaceuticals, Inc. (AERI)

(Delayed Data from NSDQ)

$39.78 USD

39.78
361,007

+1.23 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.78 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals

SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.

Talaris (TALS) Down on Patient Death From Renal Transplant Study

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

Vaishali Doshi headshot

Add These 4 Top-Ranked Liquid Stocks For Healthy Gains

Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.

Nalak Das headshot

5 Small Hidden Gems Flying High Despite Market's Bloodbath

We have narrowed our search to five small cap stocks that have provided more than 35% returns year to date,These are: AERI, AMAL, RELL, PHX and SBOW.

Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics

Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.

RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate

RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.

    Corcept (CORT) Thrives on Korlym, Overdependence a Concern

    Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

      Kinjel Shah headshot

      5 Stocks to Bet on in an Innovation-Driven Drug Industry

      Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

      Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

      The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

      Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing

      The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.

      Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?

      Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.

      Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

      Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

      Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab

      Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.

      United Therapeutics (UTHR) Initiates Tyvaso Study in IPF

      United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.

      Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

      Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

      GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns

      Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.

      Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

      Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

      KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

      KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

      Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?

      Here is how Aerie Pharmaceuticals (AERI) and Hanger (HNGR) have performed compared to their sector so far this year.

      Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

      Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

      Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

      Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

      Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

      Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.